Conservative oxygen target,
does it really help with Lower all-cause mortality in critically ill adults?
research showsThe grade is D. UK-ROX randomized 16,500 mechanically ventilated adults to an SpO2 target of 90% (range 88-92%) or usual oxygen. Ninety-day mortality was 35.4% versus 34.9%, adjusted risk difference +0.7 points (95% CI -0.7 to +2.0). No validated minimum mortality-benefit threshold was identified, so this is D rather than F.
ads claimLess oxygen is not one uniform treatment. The SpO2 or PaO2 target, range, comparator ceiling, duration, and population must be specified.
Useful facts when choosing a product
- UK-ROX targeted SpO2 90% with an 88-92% range.
- HOT-ICU tested PaO2 targets of 60 versus 90 mm Hg.
- Serious adverse events in UK-ROX were 0.7% versus 0.4%, without a significant mortality subgroup interaction.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.conservative-oxygen-target.UNK.all-cause-mortality-in-critically-ill-adults.reduce.UNKUnknown > Conservative oxygen target > Unknown > all-cause mortality in critically ill adults > Reduction claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
UK-ROX analyzed 16,394 participants for the primary outcome, with 2908/8211 versus 2858/8183 deaths. ICU-ROX randomized 1,000 and found 21.3 versus 22.1 ventilator-free days; 180-day mortality was 170/476 versus 164/475. HOT-ICU randomized 2,928 and analyzed mortality in 2,888. PILOT included 2,541 in its primary analysis.
Why this is classified as D (34)
The most direct large mortality trial was null, and no validated benefit-exclusion boundary supports F; D with 34 points.
Counterpoint. Signals in ARDS, sepsis, or hypoxic-ischemic encephalopathy subgroups remain exploratory.
Rejudgment record. Cross-check applied — A precise null 90-day mortality result in UK-ROX, trial-to-trial target differences, and no validated benefit threshold
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
Stored derived and displayed grades match; this is not a current recalculation or validity check (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Lower 90-day mortality with an SpO2 target of 88-92% | D | UK-ROX found 35.4% versus 34.9%. |
| Lower 90-day mortality with a PaO2 target of 60 mm Hg | D | HOT-ICU found 42.9% versus 42.4%. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Martin et al. 2025 UK-ROX | Multicenter pragmatic registry-embedded randomized trial | 16,500 randomized; 16,394 with primary outcome | UK National Institute for Health and Care Research | 90-day all-cause mortality | 2908/8211 (35.4%) vs 2858/8183 (34.9%), adjusted RD +0.7 points (-0.7 to +2.0) | Largest and most direct mortality trial |
| ICU-ROX Investigators 2020 | Multicenter randomized trial | 1,000 randomized; 951 with 180-day mortality | Health Research Council of New Zealand | Primary 28-day ventilator-free days; secondary 90- and 180-day mortality | Ventilator-free days 21.3 vs 22.1; 180-day mortality 35.7% vs 34.5% | Indirect because target and primary endpoint differed |
| Schjørring et al. 2021 HOT-ICU | Multicenter randomized trial | 2,928 randomized; 2,888 in mortality analysis | Innovation Fund Denmark and public/nonprofit funders | 90-day all-cause mortality | 618/1441 (42.9%) vs 613/1447 (42.4%), RR 1.02 (0.94-1.11) | Acute hypoxemic respiratory failure trial with different PaO2 targets |
| Semler et al. 2022 PILOT | Cluster-randomized cluster-crossover trial | 2,541 in primary analysis | US National Heart, Lung, and Blood Institute and others | Ventilator-free days through day 28 | Medians 20, 21, and 21 days; 28-day in-hospital mortality 34.8%, 34.0%, and 33.2% | Not direct replication because it used three targets and a different primary endpoint |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-08-07).
Final verification and publication gate: Codex · Evidence date: 2026-08-07 · Corrections: none
Cite this verdict
[Chamgap] Conservative oxygen target x ICU mortality — Evidence Grade D·34. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/conservative-oxygen-target-icu-mortality/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.